CA1239582A - Reactif de dosages immunologiques compose de vesicules de lipides et methode - Google Patents

Reactif de dosages immunologiques compose de vesicules de lipides et methode

Info

Publication number: CA1239582A
Authority: CA; Canada
Prior art keywords: molecules; reagent; lipid; vehicles; antibody
Prior art date: 1984-05-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000455271A

Other languages

English (en)

Inventor

Pedro E. Huertas

Francis J. Martin

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

COOPER-LIPOTECH Inc

Original Assignee

COOPER-LIPOTECH Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-05-28

Filing date

1984-05-28

Publication date

1988-07-26

1984-05-28 Application filed by COOPER-LIPOTECH Inc filed Critical COOPER-LIPOTECH Inc

1984-05-28 Priority to CA000455271A priority Critical patent/CA1239582A/fr

1988-07-26 Application granted granted Critical

1988-07-26 Publication of CA1239582A publication Critical patent/CA1239582A/fr

Status Expired legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 60
239000003153 chemical reaction reagent Substances 0.000 title abstract description 136
238000003556 assay Methods 0.000 title abstract description 24
150000002632 lipids Chemical class 0.000 claims abstract description 121
239000012491 analyte Substances 0.000 claims abstract description 22
238000009739 binding Methods 0.000 claims description 78
230000027455 binding Effects 0.000 claims description 76
210000004027 cell Anatomy 0.000 claims description 38
239000000427 antigen Substances 0.000 claims description 29
102000036639 antigens Human genes 0.000 claims description 27
108091007433 antigens Proteins 0.000 claims description 27
210000003743 erythrocyte Anatomy 0.000 claims description 18
102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 11
108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 11
239000000725 suspension Substances 0.000 claims description 11
230000001413 cellular effect Effects 0.000 claims description 3
230000003993 interaction Effects 0.000 claims description 3
102000004190 Enzymes Human genes 0.000 abstract description 95
108090000790 Enzymes Proteins 0.000 abstract description 95
239000003446 ligand Substances 0.000 abstract description 76
230000000694 effects Effects 0.000 abstract description 31
238000003018 immunoassay Methods 0.000 abstract description 21
239000012071 phase Substances 0.000 abstract description 11
239000007791 liquid phase Substances 0.000 abstract description 5
239000007788 liquid Substances 0.000 abstract description 3
238000005192 partition Methods 0.000 abstract 1
239000003981 vehicle Substances 0.000 description 187
229940088598 enzyme Drugs 0.000 description 94
239000002502 liposome Substances 0.000 description 70
239000007787 solid Substances 0.000 description 50
238000005859 coupling reaction Methods 0.000 description 30
238000006243 chemical reaction Methods 0.000 description 27
102000004169 proteins and genes Human genes 0.000 description 27
108090000623 proteins and genes Proteins 0.000 description 27
238000002360 preparation method Methods 0.000 description 22
238000010168 coupling process Methods 0.000 description 21
102000005936 beta-Galactosidase Human genes 0.000 description 20
108010005774 beta-Galactosidase Proteins 0.000 description 20
230000008878 coupling Effects 0.000 description 19
239000012634 fragment Substances 0.000 description 16
150000003904 phospholipids Chemical class 0.000 description 15
230000002829 reductive effect Effects 0.000 description 15
230000008901 benefit Effects 0.000 description 11
230000001965 increasing effect Effects 0.000 description 11
239000000203 mixture Substances 0.000 description 11
239000011521 glass Substances 0.000 description 10
239000000243 solution Substances 0.000 description 10
241000894007 species Species 0.000 description 9
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
239000002245 particle Substances 0.000 description 8
-1 phosphatidylcholine Chemical class 0.000 description 8
239000012429 reaction media Substances 0.000 description 8
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
239000012530 fluid Substances 0.000 description 7
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
239000003599 detergent Substances 0.000 description 6
230000005484 gravity Effects 0.000 description 6
239000000376 reactant Substances 0.000 description 6
230000009257 reactivity Effects 0.000 description 6
238000012360 testing method Methods 0.000 description 6
ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 5
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
230000021615 conjugation Effects 0.000 description 5
238000001704 evaporation Methods 0.000 description 5
230000006870 function Effects 0.000 description 5
238000006722 reduction reaction Methods 0.000 description 5
230000002441 reversible effect Effects 0.000 description 5
201000005404 rubella Diseases 0.000 description 5
239000000523 sample Substances 0.000 description 5
230000009870 specific binding Effects 0.000 description 5
235000012000 cholesterol Nutrition 0.000 description 4
230000000295 complement effect Effects 0.000 description 4
238000001085 differential centrifugation Methods 0.000 description 4
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 4
230000008020 evaporation Effects 0.000 description 4
230000009871 nonspecific binding Effects 0.000 description 4
FOKWMWSOTUZOPN-UHFFFAOYSA-N octamagnesium;iron(2+);pentasilicate Chemical compound [Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Fe+2].[Fe+2].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] FOKWMWSOTUZOPN-UHFFFAOYSA-N 0.000 description 4
238000012856 packing Methods 0.000 description 4
239000011025 peridot Substances 0.000 description 4
239000004417 polycarbonate Substances 0.000 description 4
229920000515 polycarbonate Polymers 0.000 description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
230000009467 reduction Effects 0.000 description 4
230000035945 sensitivity Effects 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
238000000527 sonication Methods 0.000 description 4
239000000758 substrate Substances 0.000 description 4
238000005406 washing Methods 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
241000604739 Phoebe Species 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
229910052786 argon Inorganic materials 0.000 description 3
239000000872 buffer Substances 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
238000009792 diffusion process Methods 0.000 description 3
238000009826 distribution Methods 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
230000002779 inactivation Effects 0.000 description 3
238000011534 incubation Methods 0.000 description 3
125000003473 lipid group Chemical group 0.000 description 3
239000012528 membrane Substances 0.000 description 3
239000000178 monomer Substances 0.000 description 3
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 3
230000035484 reaction time Effects 0.000 description 3
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical group CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
239000004743 Polypropylene Substances 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
238000013019 agitation Methods 0.000 description 2
125000001931 aliphatic group Chemical group 0.000 description 2
238000013459 approach Methods 0.000 description 2
102000023732 binding proteins Human genes 0.000 description 2
108091008324 binding proteins Proteins 0.000 description 2
239000003593 chromogenic compound Substances 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
238000004132 cross linking Methods 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
229910000397 disodium phosphate Inorganic materials 0.000 description 2
235000019800 disodium phosphate Nutrition 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
238000001125 extrusion Methods 0.000 description 2
238000002523 gelfiltration Methods 0.000 description 2
239000005556 hormone Substances 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
230000000887 hydrating effect Effects 0.000 description 2
230000002427 irreversible effect Effects 0.000 description 2
239000002523 lectin Substances 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
239000013642 negative control Substances 0.000 description 2
239000003791 organic solvent mixture Substances 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
229920001155 polypropylene Polymers 0.000 description 2
239000002243 precursor Substances 0.000 description 2
125000004076 pyridyl group Chemical group 0.000 description 2
239000011535 reaction buffer Substances 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
239000012266 salt solution Substances 0.000 description 2
238000009738 saturating Methods 0.000 description 2
238000000926 separation method Methods 0.000 description 2
238000013207 serial dilution Methods 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
239000001488 sodium phosphate Substances 0.000 description 2
238000000638 solvent extraction Methods 0.000 description 2
239000011877 solvent mixture Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
150000003573 thiols Chemical class 0.000 description 2
238000007039 two-step reaction Methods 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
PYVRVRFVLRNJLY-KTKRTIGZSA-N 1-oleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)COP(O)(=O)OCCN PYVRVRFVLRNJLY-KTKRTIGZSA-N 0.000 description 1
HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
241000857945 Anita Species 0.000 description 1
241000879217 Apocynum androsaemifolium Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
BHYOQNUELFTYRT-UHFFFAOYSA-N Cholesterol sulfate Natural products C1C=C2CC(OS(O)(=O)=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 BHYOQNUELFTYRT-UHFFFAOYSA-N 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
229930186217 Glycolipid Natural products 0.000 description 1
108010093096 Immobilized Enzymes Proteins 0.000 description 1
102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
235000007279 Lewisia rediviva Nutrition 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
239000005089 Luciferase Substances 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
101710160107 Outer membrane protein A Proteins 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
239000002262 Schiff base Substances 0.000 description 1
150000004753 Schiff bases Chemical class 0.000 description 1
235000018087 Spondias lutea Nutrition 0.000 description 1
LEBBDRXHHNYZIA-LDUWYPJVSA-N [(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] n-[(z)-1,3-dihydroxyoctadec-4-en-2-yl]carbamate Chemical compound CCCCCCCCCCCCC\C=C/C(O)C(CO)NC(=O)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O LEBBDRXHHNYZIA-LDUWYPJVSA-N 0.000 description 1
230000004520 agglutination Effects 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
238000004873 anchoring Methods 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000012300 argon atmosphere Substances 0.000 description 1
238000003491 array Methods 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000002585 base Substances 0.000 description 1
239000011324 bead Substances 0.000 description 1
WPIHMWBQRSAMDE-YCZTVTEBSA-N beta-D-galactosyl-(1->4)-beta-D-galactosyl-N-(pentacosanoyl)sphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@@H]1O[C@H](CO)[C@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)\C=C\CCCCCCCCCCCCC WPIHMWBQRSAMDE-YCZTVTEBSA-N 0.000 description 1
230000003851 biochemical process Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
210000002390 cell membrane structure Anatomy 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
BHYOQNUELFTYRT-DPAQBDIFSA-N cholesterol sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 BHYOQNUELFTYRT-DPAQBDIFSA-N 0.000 description 1
150000001841 cholesterols Chemical class 0.000 description 1
WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000013068 control sample Substances 0.000 description 1
239000005289 controlled pore glass Substances 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000008344 egg yolk phospholipid Substances 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
150000002270 gangliosides Chemical class 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229930182470 glycoside Natural products 0.000 description 1
150000002338 glycosides Chemical class 0.000 description 1
229940098197 human immunoglobulin g Drugs 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
229940027941 immunoglobulin g Drugs 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000000464 low-speed centrifugation Methods 0.000 description 1
125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
125000006501 nitrophenyl group Chemical group 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
239000003973 paint Substances 0.000 description 1
239000013618 particulate matter Substances 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
150000003905 phosphatidylinositols Chemical class 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000013641 positive control Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000013557 residual solvent Substances 0.000 description 1
239000012488 sample solution Substances 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000003270 steroid hormone Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000006557 surface reaction Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000010409 thin film Substances 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1
239000013026 undiluted sample Substances 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
HFQKBOPMAOTAIR-TZSVBWBLSA-N α-d-galactosyl-(1->4)-β-d-galactosyl-(1->4)-β-d-glucosylceramide Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)NC(C)=O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 HFQKBOPMAOTAIR-TZSVBWBLSA-N 0.000 description 1

Landscapes

Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

CA000455271A 1984-05-28 1984-05-28 Reactif de dosages immunologiques compose de vesicules de lipides et methode Expired CA1239582A (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA000455271A CA1239582A (fr)	1984-05-28	1984-05-28	Reactif de dosages immunologiques compose de vesicules de lipides et methode

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA000455271A CA1239582A (fr)	1984-05-28	1984-05-28	Reactif de dosages immunologiques compose de vesicules de lipides et methode

Publications (1)

Publication Number	Publication Date
CA1239582A true CA1239582A (fr)	1988-07-26

Family

ID=4127953

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000455271A Expired CA1239582A (fr)	1984-05-28	1984-05-28	Reactif de dosages immunologiques compose de vesicules de lipides et methode

Country Status (1)

Country	Link
CA (1)	CA1239582A (fr)

1984
- 1984-05-28 CA CA000455271A patent/CA1239582A/fr not_active Expired

Legal Events

Date	Code	Title	Description
2005-07-26	MKEX	Expiry

Publication	Publication Date	Title
US4636479A (en)	1987-01-13	Enhanced agglutination method and kit
US4783400A (en)	1988-11-08	Homogeneous enzyme immunoassay system and method
US4605630A (en)	1986-08-12	Large-liposome agglutination reagent and method
US4704355A (en)	1987-11-03	Assay utilizing ATP encapsulated within liposome particles
US4598051A (en)	1986-07-01	Liposome conjugates and diagnostic methods therewith
EP0900382B1 (fr)	2002-08-07	Dosages immunologiques de detection d'anticorps antiphospholipides
WO1984002579A1 (fr)	1984-07-05	Procede et reactif d'essai de surface de vesicules lipidiques
US4752572A (en)	1988-06-21	Lipid vesicles containing labeled species and their analytical uses
US4745074A (en)	1988-05-17	Blood-fluid composition for cell lysis system
US4839276A (en)	1989-06-13	Interference - resistant liposome specific binding assay
US5210040A (en)	1993-05-11	Process for coupling antibodies or antibody fragments to liposomes
EP0243471A1 (fr)	1987-11-04	Systeme d'immunoanalyse a base de liposomes en phase solide
CA1239582A (fr)	1988-07-26	Reactif de dosages immunologiques compose de vesicules de lipides et methode
EP0276165A1 (fr)	1988-07-27	Liposomes susceptibles de localiser certains objets et leur utilisation dans un immuno-essai
US4971916A (en)	1990-11-20	Liposome based homogeneous immunoassay for diagnostic tests
CA1309344C (fr)	1992-10-27	Dosage immunologique homogene a base de liposome pour epreuves diagnostiques
Kung et al.	1986	Large liposome agglutination technique for the serological detection of syphilis
EP0184701A2 (fr)	1986-06-18	Procédé pour déterminer un ligand
JP4250704B2 (ja)	2009-04-08	乾式免疫測定試薬
JP2003149246A (ja)	2003-05-21	物質の検出法
JP2639573B2 (ja)	1997-08-13	補体測定用リポソームおよびそれを用いる補体測定法
JPH01229970A (ja)	1989-09-13	補体測定法
Kung et al.	1989	Recent Developments in the use of Liposomes in in vitro Diagnostic Assays
JP2000235034A6 (ja)	2009-01-15	乾式免疫測定試薬
JP2000235033A (ja)	2000-08-29	高感度免疫測定試薬